Mizuho reiterated their neutral rating on shares of Icon (NASDAQ:ICLR) in a report released on Thursday morning, Marketbeat reports. They currently have a $114.00 price objective on the medical research company’s stock, up from their prior price objective of $109.00.
Several other research firms have also weighed in on ICLR. Zacks Investment Research raised shares of Icon from a hold rating to a buy rating and set a $132.00 target price for the company in a report on Tuesday, January 9th. BidaskClub raised shares of Icon from a strong sell rating to a sell rating in a report on Friday, February 9th. SunTrust Banks reaffirmed a buy rating and set a $138.00 target price on shares of Icon in a report on Sunday, October 29th. Evercore ISI started coverage on shares of Icon in a report on Thursday, January 18th. They set an outperform rating and a $126.00 target price for the company. Finally, KeyCorp reaffirmed an overweight rating and set a $125.00 target price (up from $115.00) on shares of Icon in a report on Monday, November 13th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average price target of $126.00.
Icon (NASDAQ ICLR) opened at $115.01 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.90 and a current ratio of 1.90. The firm has a market cap of $6,228.02, a P/E ratio of 21.38, a PEG ratio of 1.62 and a beta of 0.48. Icon has a 1-year low of $76.46 and a 1-year high of $124.48.
Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, February 15th. The medical research company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.41 by $0.02. The firm had revenue of $455.10 million during the quarter, compared to analyst estimates of $455.66 million. Icon had a net margin of 16.01% and a return on equity of 28.60%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.33 EPS. sell-side analysts anticipate that Icon will post 6.01 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. WCM Investment Management CA increased its holdings in Icon by 5.8% in the 4th quarter. WCM Investment Management CA now owns 4,281,211 shares of the medical research company’s stock worth $480,138,000 after acquiring an additional 233,990 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Icon by 1.0% in the 4th quarter. Alliancebernstein L.P. now owns 2,560,367 shares of the medical research company’s stock worth $287,145,000 after acquiring an additional 24,571 shares in the last quarter. Clearbridge Investments LLC increased its holdings in Icon by 1.0% in the 4th quarter. Clearbridge Investments LLC now owns 1,897,429 shares of the medical research company’s stock worth $212,797,000 after acquiring an additional 18,041 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Icon by 37.5% in the 4th quarter. Renaissance Technologies LLC now owns 1,817,307 shares of the medical research company’s stock worth $203,811,000 after acquiring an additional 495,247 shares in the last quarter. Finally, Boston Partners increased its holdings in Icon by 0.5% in the 4th quarter. Boston Partners now owns 1,111,725 shares of the medical research company’s stock worth $124,680,000 after acquiring an additional 5,314 shares in the last quarter. 89.18% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Icon (ICLR) Earns Neutral Rating from Mizuho” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/19/icon-iclr-earns-neutral-rating-from-mizuho-2.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.